Unknown

Dataset Information

0

Relationship between molecular response and quality of life with bosutinib or imatinib for chronic myeloid leukemia.


ABSTRACT: Patients with newly diagnosed chronic phase chronic myeloid leukemia (CP CML) can be effectively treated with tyrosine kinase inhibitors (TKIs) and achieve a lifespan similar to the general population. The success of TKIs, however, requires long-term and sometimes lifelong treatment; thus, patient-assessed health-related quality of life (HRQoL) has become an increasingly important parameter for treatment selection. Bosutinib is a TKI approved for CP CML in newly diagnosed adults and in those resistant or intolerant to prior therapy. In the Bosutinib Trial in First-Line Chronic Myelogenous Leukemia Treatment (BFORE), bosutinib demonstrated a significantly higher major molecular response rate compared with imatinib, with maintenance of HRQoL (measured by the Functional Assessment of Cancer Therapy-Leukemia (FACT-Leu) questionnaire), after 12 months of first-line treatment. We examined relationships between molecular response (MR) and HRQoL. MR values were represented by a log-reduction scale (MRLR; a continuous variable). A repeated-measures longitudinal model was used to estimate the relationships between MRLR as a predictor and each FACT-Leu domain as an outcome. Effect sizes were calculated to determine strength of effects and allow comparisons across domains. The majority of FACT-Leu domains (with the exception of social well-being and physical well-being) demonstrated a significant relationship with MRLR (p?

SUBMITTER: Brummendorf TH 

PROVIDER: S-EPMC7237399 | biostudies-literature | 2020 Jun

REPOSITORIES: biostudies-literature

altmetric image

Publications

Relationship between molecular response and quality of life with bosutinib or imatinib for chronic myeloid leukemia.

Brümmendorf Tim H TH   Gambacorti-Passerini Carlo C   Bushmakin Andrew G AG   Cappelleri Joseph C JC   Viqueira Andrea A   Reisman Arlene A   Isfort Susanne S   Mamolo Carla C  

Annals of hematology 20200419 6


Patients with newly diagnosed chronic phase chronic myeloid leukemia (CP CML) can be effectively treated with tyrosine kinase inhibitors (TKIs) and achieve a lifespan similar to the general population. The success of TKIs, however, requires long-term and sometimes lifelong treatment; thus, patient-assessed health-related quality of life (HRQoL) has become an increasingly important parameter for treatment selection. Bosutinib is a TKI approved for CP CML in newly diagnosed adults and in those res  ...[more]

Similar Datasets

| S-EPMC4979199 | biostudies-literature
| S-EPMC5966023 | biostudies-literature
| S-EPMC9252917 | biostudies-literature
| S-EPMC7948290 | biostudies-literature
| S-EPMC4916559 | biostudies-literature
| S-EPMC5303616 | biostudies-literature
| S-EPMC6518910 | biostudies-literature
| S-EPMC4305212 | biostudies-literature
| S-EPMC9414005 | biostudies-literature
| S-EPMC4173127 | biostudies-literature